What is the FDA Orange Book pediatric exclusivity database?
The FDA’s Orange Book is the searchable database of approved drug products and, for many products, it also includes details tied to patents and exclusivity periods. Users often refer to it as the place to check “pediatric exclusivity,” meaning additional marketing exclusivity for drugs that meet certain pediatric study requirements set by U.S. law. The Orange Book is managed by FDA and can be searched by drug name, active ingredient, and product details.
How do you look up pediatric exclusivity in the Orange Book?
In practice, the workflow is:
1. Go to the FDA Orange Book database.
2. Search for the active ingredient (or brand name) of the drug.
3. Open the relevant listing for the specific product.
4. Check the exclusivity information shown for that listing, which can include pediatric exclusivity timing alongside other exclusivity or patent-related entries.
Because “pediatric exclusivity” is tied to specific exclusivity codes/entries in the record, the most reliable approach is to use the exact drug search and then read the exclusivity portion of the listing for that product.
Can pediatric exclusivity affect generic or biosimilar entry dates?
Yes. Pediatric exclusivity can extend the period during which approved generic drug products (and in some cases other market-competition pathways) are limited from entering with certain “carve-outs” or application types. The Orange Book record is the main public place to verify whether a specific product has pediatric exclusivity reflected in the exclusivity section of its approval record.
Where does DrugPatentWatch fit in?
DrugPatentWatch.com often mirrors and structures patent/exclusivity intelligence (including pediatric exclusivity-related items) to make it easier to track expiration timelines and competitive risk around specific products. You can use it alongside the FDA Orange Book when you need a cross-check or a more user-friendly expiration view: DrugPatentWatch.com.
Common search mistakes people make
People sometimes search the Orange Book by the brand name but not the correct active ingredient, or they look at the wrong strength/formulation listing. Pediatric exclusivity is recorded at the product/approval listing level, so it’s important to match the exact Orange Book listing that corresponds to the formulation you care about.
If you tell me the drug name, can I point to the right Orange Book listing?
Yes. Share the active ingredient or brand name (and strength/formulation if you have it), and I can help you identify what to check in the Orange Book record for pediatric exclusivity (timing and whether it’s present on that specific listing).
Sources
- DrugPatentWatch.com